Enzalutamide

Phase 3

Astellas Pharma (ALPMY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Oct '27

ALPMYPhase 2$27.2B

Enzalutamide Phase 2 Est. Readout

Enzalutamide• Progressive Metastatic Prostate Cancer201

Oct 2027~Estimated

CT.gov

00%

May '27

ALPMYPhase 2$27.2B

Enzalutamide Phase 2 Est. Readout

Enzalutamide• Progressive Metastatic Prostate Cancer50

May 2027~Estimated

CT.gov

00%

Dec '26

ALPMYPhase 3$27.2B

Enzalutamide Phase 3 Est. Readout (ENZAMET)

Enzalutamide• Progressive Metastatic Prostate Cancer1,125

Dec 2026~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Progressive Metastatic Prostate Cancer

View Full Landscape

Drug Information

Target Indication

Progressive Metastatic Prostate Cancer

Clinical Trial

NCT02294461

Last updated: 12/24/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ALPMY

Astellas Pharma

Healthcare•North America•NASDAQ

Related Pipeline

OPT-80Phase 3

Clostridium Difficile

VernakalantPhase 3

Atrial Flutter

daclizumabPhase 3

Kidney Transplantation

SetidegrasibPhase 3

Pancreatic Cancer

YM177Phase 3

Post Operative Pain

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts